Table 3. Characteristics of individual drugs for use in TBM.
| Anti-TB activity |
Clinical efficacy in TBM |
Site of disease exposure |
Safety/ tolerability |
Drug-drug interactions |
Access | |
|---|---|---|---|---|---|---|
| Rifampicin | 3 | 2 | 3 | 2 | 0 | 2 |
| Isoniazid | 3 | 2 | 3 | 2 | 1 | 2 |
| Linezolid 74 | 2 | 2 | 3 | 1 | 1 | 2 |
| Fluoroquinolones 50 | 3 | 2 | 3 | 2 | 1 | 2 |
| Pyrazinamide | 2 | 2 | 3 | 2 | 1 | 2 |
| Pretomanid/delamanid 75 | 3 | 1 | 3 | 2 | 1 | 2 |
| Bedaquiline | 3 | 1 | 2 | 2 | 0 | 2 |
| Alpibectir/ethionamide | 2 | 0 | 3 | 2 | 1 | |
| Rifabutin | 3 | 0 | 2 | 2 | 0 | 2 |
| Clofazimine | 1 | 0 | 1 | 2 | 1 | 2 |
| Ethionamide | 1 | 2 | 2 | 1 | 2 | |
| Cycloserine | 1 | 0 | 2 | 1 | 2 | |
| Ethambutol | 1 | 2 | 1 | 2 | ||
| DprE1 inhibitors | 3 | 0 | 0 | 2 | 1 |
Scores derived from the scoring system in Table 2.